Eskandary F, et al. - This trial was designed to find out if 2 cycles of bortezomib (each cycle: 1.3 mg/m² intravenously on days 1, 4, 8, and 11) prevent GFR decline by halting the progression of late donor-specific antibody (DSA)–positive antibody-mediated rejection (ABMR). This inquiry afforded no evidence that bortezomib prevents GFR loss, improves histologic or molecular disease features, or reduces DSA, despite significant toxicity.